Frontlight ResearchEarly access
Taking peoplePhase 1
Testing DO-2 in adults with advanced or hard-to-treat solid tumours
Tests DO-2, a MET inhibitor, in adults with advanced solid tumours.
Key facts
- Who runs it
- Deuteroncology
- Where
- Gdansk, Lodz, Lublin, and Wroc?aw, PolandSee the 4 sitesAlso in 4 other countries, 17 sites
- Registry title
- A Phase 1 Study to Determine the Safety, and Pharmacokinetics of the Selective MET kinase Inhibitor, DO-2 in Patients With Advanced or Refractory Solid Tumours
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 138 people, planned
- Started
- 13 Apr 2023
- Expected to end
- 1 Jun 2027
- Type of study
- Interventional
- Record updated
- 12 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced or hard-to-treat solid tumours (Part 1), and adults with advanced non-small cell lung cancer that cannot be removed by surgery or has spread (Part 2).
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Part 1: advanced or refractory solid tumours. Part 2: locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC).
Main reasons for not taking part
- Healthy volunteers cannot join
Where in Poland
Also in 4 other countries, 17 sites
- Centrum Wsparcia Badań Klinicznych UCK Ośrodek Badań Klinicznych Wczesnych FazGdansk, PolandNot yet recruiting
- Instytut Centrum Zdrowia Matki PolkiLodz, PolandNot yet recruiting
- Uniwersytecki Szpital Kliniczny nr 4 w LublinieLublin, PolandNot yet recruiting
- Dolnoslaskie Centrum Onkologii, Pulmonologii i HematologiiWroc?aw, PolandNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Plain-language title
- Testing DO-2 in adults with advanced or hard-to-treat solid tumoursGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 12 August 2026